All In Biotech

Drug Trial Radar · NCT07511361

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part Study to Evaluate the Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Jun 23, 2026

Primary completion

Dec 2026

Study completion Feb 2027

Sponsor

Lead sponsor
Kardigan, Inc.Industry
Sponsor type
Industry
First posted
Apr 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.

Conditions

  • Hypertension
  • Acute Severe Hypertension
  • Hypertensive Emergency
  • Hypertensive Urgency

Interventions

  • TonlamarsenDrug

    Tonlamarsen will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study

  • PlaceboDrug

    Placebo will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptionsTime frame: Baseline through Week 12
  2. Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levelsTime frame: Week 4

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Western Nephrology and Metabolic Bone Disease, PC - Arvada

    Arvada, Colorado · Recruiting

  • Homestead Associates in Research

    Homestead, Florida · Recruiting

  • Progressive Medical Research

    Port Orange, Florida · Recruiting

  • Eagle Clinical Research

    Chicago, Illinois · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Richmond University Medical Center (RUMC)

    Staten Island, New York · Active not recruiting

  • Research Innovations, LLC

    Beavercreek, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • OnSite Clinical Solutions, LLC

    Fort Mill, South Carolina · Recruiting

  • Chattanooga Research & Medicine CHARM

    Chattanooga, Tennessee · Recruiting

  • Laguna Clinical Research Associates

    Laredo, Texas · Recruiting

  • Tapia Internal Medicine Clinic

    Paris, Texas · Recruiting

  • Baylor Scott and White Research Institute - Temple

    Temple, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.